Inflammatory disease Archives

Inflazome Forbion inflammatory disease macrophage

More News! 19 Nov 2018

Anti-Inflammatory Treatments Get €40M Boost in Series B

A Series B funding round has whipped up €40M for the Irish company Inflazome. This money will help to fund clinical trials for anti-inflammatory treatments targeting conditions such as Alzheimer’s and Parkinson’s disease. “We are extremely excited about this opportunity, which is such a large funding round in a European company,” Marco Boorsma, General Partner […]

November 19, 2018 - 2 minutesmins - By Jonathan Smith

Sitryx immunometabolism cancer inflammation

News and Trends 8 Oct 2018

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Sitryx has launched today with the goal of treating cancer and inflammatory conditions by targeting the metabolism of immune cells, a promising area of research. The new company has kicked off with a €26M Series A round co-led by two specialized investors, SV Health and Sofinnova Partners. Sitryx also has investment from GSK, with […]

October 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Inotrem Septic Shock Blood Infection Header

News and Trends 2 Oct 2018

Septic Shock Drug Shows Promise for Personalized Medicine

Septic shock may no longer be as shocking in the future, as a Phase IIa trial brings hope for a personalized immunomodulatory treatment from the French biotech Inotrem. In sepsis, the immune system overreacts to the infection of a pathogen, causing uncontrolled inflammation throughout the body and organ failure. This can lead to septic […]

October 2, 2018 - 2 minutesmins - By Jonathan Smith

More News! 24 Aug 2018

Shire gets US market approval for rare inflammatory disease drug

The UK-US biotech giant’s drug Takhzyro has been approved by the FDA to prevent attacks of hereditary angioedema, a rare genetic disease that causes swelling around the body. Hereditary angioedema is a potentially life threatening genetic condition that people can inherit from either of their parents. Takhzyro (lanadelumab-flyo) is a first-in-class monoclonal antibody drug that […]

August 24, 2018 - 2 minutesmins - By Helen Albert

News and Trends 22 Aug 2018

Swedish Biotech Breaks Barrier to Diagnosis with Rheumatoid Arthritis Test

A blood test developed by Swedish-biotech Immunovia and scientists from Linköping University accurately diagnoses patients with rheumatoid arthritis even if they test negative for two common biomarkers. The current gold standard test for rheumatoid arthritis, which affects 5-7 million people in the US and Europe, misses a substantial number of people who have the condition. […]

August 22, 2018 - 2 minutesmins - By Helen Albert

News and Trends 31 Jul 2018

Israeli Crohn’s Disease Drug Rakes in Positive Phase III Results

RedHill Biopharma has obtained positive Phase III results for its Crohn’s disease treatment, which targets a certain type of gut bacteria. Crohn’s disease is a type of inflammatory bowel disease, characterized by acute flare-ups and periods of symptom-free remission, that can affect any part of the gastrointestinal tract. It has a high prevalence for an autoimmune disease, […]

July 31, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 5 Jul 2018

Series A Round Could Bring French Microbiome Treatment for Bowel Disease Into the Clinic

Netbiotix has raised €7.5M to bring its lead candidate for inflammatory bowel disease into clinical trials. The treatment uses a bacterium found in the gut to prevent and dampen inflammation. The company, based in Paris, develops treatments for inflammatory bowel disease (IBD) that consist of a single microbial strain that interacts with cells in the […]

July 5, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 7 Jun 2018

Microbiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD

UK biotech Microbiotica has entered into a multi-year collaboration with Genentech, one of the world’s first biotechs, to develop microbiome-based treatments for inflammatory bowel disease. Microbiotica, based in Cambridge, UK has entered into a collaboration with Genentech that could be worth up to €452M ($534M), a formidable amount in the microbiome space, with an undisclosed […]

June 7, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 6 Jun 2018

German DNA Treatment Reduces Ulcerative Colitis Symptoms

Sterna Biologicals has obtained positive Phase IIa data for an ulcerative colitis treatment that uses DNA to inhibit inflammatory proteins, which could add to the diverse approaches being developed to treat inflammatory bowel disease. Sterna Biologicals, based in Marburg, Germany, has clinical data showing its ulcerative colitis treatment reduced the severity of the disease compared […]

June 6, 2018 - 3 minutesmins - By Alexander Burik

Niels Riedemann InflaRx Cover Image Compressed

Interview 11 Apr 2018

Forget Humira, a New Generation of Inflammation Treatments is on the Horizon

Millions of people worldwide suffer from inflammatory diseases, and many are still waiting for effective treatments. A German company, InflaRx, might have one. We spoke to its founder and CEO, Niels Riedemann, to get the whole story about the company’s technology and its recent $106M IPO on NASDAQ. It might be hard to believe, but […]

April 11, 2018 - 5 minutesmins - By Alexander Burik

tigenix alofisel takeda stem cell therapy crohns disease

News and Trends 27 Mar 2018

Stem Cell Therapy for Crohn’s Disease Approved in Europe

Developed by TiGenix, Alofisel is the first stem cell therapy made out of donor stem cells to receive a marketing authorization in Europe. The European Commission has approved Alofisel (darvadstrocel), a stem cell therapy to treat complex perianal fistulas — one of the most disabling complications of Crohn’s disease. The cell therapy represents an alternative to multiple surgeries […]

March 27, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 26 Feb 2018

This Biotech Could Replace Opioids with Safe and Effective Pain Relief for Osteoarthritis

The use of opioids and non-steroidal anti-inflammatory drugs (NSAIDs) is a massive public health issue. I spoke with Simon Westbrook, CEO of Levicept, whose new approach to pain relief, which is being tested for osteoarthritis, could be a game-changer. Back in September, a couple of weeks into my time at Labiotech, I got the chance […]

February 26, 2018 - 9 minutesmins - By Alex Dale

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Inflammatory disease

Anti-Inflammatory Treatments Get €40M Boost in Series B

Oxford Biotech Launches with €26M to Target ‘Immunometabolism’

Septic Shock Drug Shows Promise for Personalized Medicine

Shire gets US market approval for rare inflammatory disease drug

Swedish Biotech Breaks Barrier to Diagnosis with Rheumatoid Arthritis Test

Israeli Crohn’s Disease Drug Rakes in Positive Phase III Results

Series A Round Could Bring French Microbiome Treatment for Bowel Disease Into the Clinic

Microbiome Company Enters $534M Deal With Genentech To Develop Treatments for IBD

German DNA Treatment Reduces Ulcerative Colitis Symptoms

Forget Humira, a New Generation of Inflammation Treatments is on the Horizon

Stem Cell Therapy for Crohn’s Disease Approved in Europe

This Biotech Could Replace Opioids with Safe and Effective Pain Relief for Osteoarthritis

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!